Clearside Biomedical

Clearside Biomedical FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 74.74 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 61.30 % — a change of 21.93% (higher).

FCF Conversion

74.74 %

YoY

21.93%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Clearside Biomedical is 2024 74.74 % . FCF Conversion Rate (FCF/EBITDA) of Clearside Biomedical was 2023 61.30 % . It decreases by 21.93% higher compared to the previous year.

The Clearside Biomedical FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
87.13 USD
Jan 1, 2018
95.74 USD
Jan 1, 2019
88.07 USD
Jan 1, 2020
72.38 USD
Jan 1, 2021
-2,823.68 USD
Jan 1, 2022
41.34 USD
Jan 1, 2023
61.30 USD
Jan 1, 2024
74.74 USD
The Clearside Biomedical FCF Conversion history
YEARFCF ConversionYoY
74.74 %+21.93%
61.30 %+48.29%
41.34 %-101.46%
-2,823.68 %-4,001.31%
72.38 %-17.82%
88.07 %-8.01%
95.74 %+9.88%
87.13 %-0.71%
87.75 %+11.12%
78.97 %-13.10%
90.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

FCF Conversion Rate (FCF/EBITDA) of Clearside Biomedical is 74.74 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Clearside Biomedical changed from 61.30 % to 74.74 %, representing a 21.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Clearside Biomedical

All Key Metrics — Clearside Biomedical